Barclays analyst Manav Patnaik maintained a Buy rating on Change Healthcare (CHNG) on April 9 and set a price target of $14.00. The company’s shares closed last Thursday at $10.49, close to its 52-week high of $11.34.
According to TipRanks.com, Patnaik is a top 100 analyst with an average return of 13.2% and a 69.7% success rate. Patnaik covers the Services sector, focusing on stocks such as Emerald Expositions Events, Laureate Education, and Factset Research.
Currently, the analyst consensus on Change Healthcare is a Strong Buy with an average price target of $18.20, implying a 72.7% upside from current levels. In a report issued on April 3, Credit Suisse also maintained a Buy rating on the stock with a $17.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $11.34 and a one-year low of $6.18. Currently, Change Healthcare has an average volume of 8.57M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Change Healthcare, Inc. operates as a healthcare technology company. It offers software, analytics, network solutions, and technology-enabled services. The firm’s products include ANSOS staff scheduling, HealthQx, hospital revenue cycle services, coding advisor, revenue performance advisor, and InterQual. The company was founded in 2007 and is headquartered in Alpharetta, GA.
